Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1706
    +0.0012 (+0.11%)
     
  • GBP/USD

    1.2629
    +0.0007 (+0.05%)
     
  • Bitcoin GBP

    56,024.13
    +935.45 (+1.70%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,301.35
    +133.28 (+0.33%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

The President of Bioanalytical Systems, Inc. (NASDAQ:BASI), Robert Leasure, Just Bought 2.2% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the Bioanalytical Systems, Inc. (NASDAQ:BASI) President, Robert Leasure, recently bought US$72k worth of stock, for US$14.42 per share. However, it only increased their shares held by 2.2%, and it wasn't a huge purchase by absolute value, either.

View our latest analysis for Bioanalytical Systems

Bioanalytical Systems Insider Transactions Over The Last Year

In fact, the recent purchase by Robert Leasure was the biggest purchase of Bioanalytical Systems shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at around the current price of US$14.64. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Bioanalytical Systems share holders is that insiders were buying at near the current price.

ADVERTISEMENT

Bioanalytical Systems insiders may have bought shares in the last year, but they didn't sell any. Their average price was about US$5.18. It is certainly positive to see that insiders have invested their own money in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Does Bioanalytical Systems Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Bioanalytical Systems insiders own about US$47m worth of shares. That equates to 29% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Do The Bioanalytical Systems Insider Transactions Indicate?

It is good to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest Bioanalytical Systems insiders are well aligned, and that they may think the share price is too low. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Bioanalytical Systems. For instance, we've identified 4 warning signs for Bioanalytical Systems (1 is concerning) you should be aware of.

Of course Bioanalytical Systems may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.